Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Regeneron Pharmaceuticals Inc (REGN), Amgen, Inc. (AMGN), Gilead Sciences, Inc. (GILD): Is College Debt a Drag on These Promising Healthcare Stocks

Page 1 of 2

Some stocks seem to have all the luck, offering the best of both worlds. They are cutting edge or at least a bit adventuresome as their products travel into uncharted territory. Innovations that they have in their pipelines are promising to push the margins even a bit further outward some time soon. Yet, despite the fact they are moving ahead at a blazing speed, they are still managing to lay down some firm financial roots, being profitable thanks at least in part to effective management.

Well, three pharmaceutical companies – Regeneron Pharmaceuticals Inc (NASDAQ:REGN)Amgen, Inc. (NASDAQ:AMGN) and Gilead Sciences, Inc. (NASDAQ:GILD) – that have developed therapies for everything from cancer and HIV to circulatory disorders seem to exemplify that perfect mix. And a review of their selling points indicates they deserve that distinction despite the fact they might be dragged down from the high perch they would otherwise enjoy by the impact of college debt.

Regeneron’s good numbers

Two simple statistics designed to measure profitability point to Regeneron Pharmaceuticals Inc (NASDAQ:REGN)’s profitability: its profit margin was measured at 52.79% and its operating margin was computed at 37.1%.

The continued expansion of its flagship product, Eylea, which treats ophthalmologic diseases such as (Wet) Age-related Macular Degeneration, has helped Regeneron Pharmaceuticals Inc (NASDAQ:REGN) compile these impressive fundamentals. Eylea’s sales for the first quarter of 2013 exceeded consensus expectations at $314 million and management estimates that revenue for the entire year will hit $1.3 billion.

And Regeneron Pharmaceuticals Inc (NASDAQ:REGN) also has in its pipeline therapies to control pain and neurotrophins, which promote the growth of nerve cells. Once available on the market, this therapy might be a welcomed addition to the emerging palliative and restorative medicine fields. And as our country ages, it might prove a boon to elders who have collected more than their share of aches and pains.

Amgen’s Promising Future

Amgen, Inc. (NASDAQ:AMGN) focuses on biologic medicines, which employs DNA technology to either insert desirable genes or remove undesirable ones. Rocket science at its best, these treatments are by many people’s opinions on track to provide “cures” for cancer and other life threatening diseases where other efforts failed.

But the fact it seems to be blazing towards the future has not inflated Amgen, Inc. (NASDAQ:AMGN)’s price into nose bleed territory. Its trailing P/E ratio, which takes into account earnings over the past 12 month period, is only 17.93; the forward P/E ratio, which is calculated on the basis of estimated future earnings is only 12.82. These statistics stack up quite favorably when compared to the average P/E ratio for health sector stocks: nearly 42. .

Gilead’s good news

Gilead Sciences, Inc. (NASDAQ:GILD)’s year to year quarterly earnings growth for the first quarter of 2013 was a hefty 63.40%. And earlier this year Gilead learned some encouraging news that might indicate this promising record will continue into the future. Its application for sofosbuvir which would be used to treat HCV (Hepatitis C Virus) infection is currently being reviewed by the European Medicines Agency (EMA).

The Center for Disease Control and Prevention estimated that 3.2 million persons in the United States have chronic Hepatitis C virus infection; so, the market for this product might be huge.

Page 1 of 2
Loading Comments...